WuXi Biologics
WuXi Biologics is a leading global Contract Research, Development, and Manufacturing Organization (CRDMO) that provides end-to-end solutions that enable partners to find, develop, and manufacture biologics from idea to commercialization for the benefit of patients all over the world.
WuXi Biologics began developing the capabilities and facilities required for biologics research, development, and GMP manufacture in 2010. In June 2017, WuXi Biologics went public on the Hong Kong Stock Exchange. WuXi Biologics will have 18 manufacturing facilities by 2021, including ten in China, three in the United States, two in Ireland, two in Germany, and one in Singapore. WuXi Biologics was chosen to be a component of the Hong Kong Hang Seng Index in August 2020.
WuXi Biologics leverages its technologies and skills to provide customers with efficient and cost-effective biologics discovery, development, and manufacturing solutions in China, the United States, Ireland, Germany, and Singapore. WuXi Biologics is supporting 588 integrated client projects, including 17 in commercial manufacturing, as of December 31, 2022.
Environmental, Social, and Governance (ESG) obligations are a fundamental part of WuXi Biologics' ethos and business strategy, and the company aspires to be an ESG leader in the biologics CRDMO sector. Their facilities make use of cutting-edge biomanufacturing technologies and clean energy sources. They have also formed an ESG committee, led by their CEO, to guide the overall ESG strategy and its implementation, thereby strengthening their commitment to sustainability.
Founded: 2015 in Wu Xi City, China
Headquarters: Primary: 108 Meiliang Road, Mashan, Binhu District, Wuxi, Jiangsu, China, 214092
Key people: Zhisheng (Chris) Chen (Chief executive officer), Jijie Gu (Chief scientific officer, Executive Vice President), Weichang Zhou (Chief technology officer, Executive Vice President), Christine Lu-Wong (Chief financial officer, Executive Vice President)
Website: https://www.wuxibiologics.com/
